WS
NAVB

Wedbush Securities’s Navidea Biopharmaceuticals Inc. NAVB Stock Holding History

Wedbush Securities’s Portfolio NAVB Stock Details NAVB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-89,208
Closed -$56K – 1058
2019
Q2 		$56K Buy
89,208
+74,258
+497% +$144K 0.01% 942
2019
Q1 		$41K Buy
14,950
+5,250
+54% +$15.5K ﹤0.01% 904
2018
Q4 		$20K Hold
9,700
– – ﹤0.01% 817
2018
Q3 		$45K Hold
9,700
– – 0.01% 877
2018
Q2 		$44K Hold
9,700
– – 0.01% 843
2018
Q1 		$70K Buy
9,700
+1,250
+15% +$9.35K 0.01% 776
2017
Q4 		$61K Buy
8,450
+7,650
+956% +$64.7K 0.01% 817
2017
Q3 		$7K Buy
+800
New +$6.78K ﹤0.01% 831

Other funds holding NAVB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $94.2B AUM 21.24% 1-Year Est. Return
ACM
Allred Capital Management Dallas, Texas $275M AUM 18.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Wedbush Securities's NAVB Position: Q3 2019 in Review

Wedbush Securities sold out of Navidea Biopharmaceuticals Inc. (NAVB) in Q3 2019, closing a stake of 89,208 shares — an estimated $56K sold.

Wedbush Securities first reported a position in NAVB in Q3 2017 and held it in 8 quarters. The position peaked at $70K in Q1 2018. 29 funds tracked by Wall St. Rank hold NAVB as of Q3 2019.

  • Wedbush Securities reported no remaining Navidea Biopharmaceuticals Inc. position as of Q3 2019 after selling out during the quarter.
  • Wedbush Securities sold 89,208 Navidea Biopharmaceuticals Inc. shares in Q3 2019, an estimated $56K.
  • Wedbush Securities first reported a position in Navidea Biopharmaceuticals Inc. in Q3 2017 and held it in 8 quarters.
  • Wedbush Securities's Navidea Biopharmaceuticals Inc. position peaked at $70K in Q1 2018.
  • 29 funds tracked by Wall St. Rank held Navidea Biopharmaceuticals Inc. as of Q3 2019.

Based on Wedbush Securities's 13F filing for Q3 2019, filed 17 Oct 2019.